ABL Bio Past Earnings Performance
Past criteria checks 0/6
ABL Bio's earnings have been declining at an average annual rate of -269.4%, while the Biotechs industry saw earnings growing at 16.6% annually. Revenues have been declining at an average rate of 66.1% per year.
Key information
-269.4%
Earnings growth rate
-269.2%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | -66.1% |
Return on equity | -75.3% |
Net Margin | -121.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Revenue & Expenses Breakdown
How ABL Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 32,955 | -40,003 | 15,526 | 55,789 |
31 Mar 24 | 33,103 | -38,952 | 15,073 | 55,391 |
31 Dec 23 | 65,547 | -2,647 | 13,493 | 52,035 |
30 Sep 23 | 67,446 | -7,951 | 14,661 | 53,845 |
30 Jun 23 | 97,254 | 23,608 | 14,275 | 53,925 |
31 Mar 23 | 104,803 | 36,101 | 14,719 | 52,347 |
31 Dec 22 | 67,301 | 3,209 | 15,569 | 48,416 |
30 Sep 22 | 57,994 | 4,352 | 14,379 | 45,801 |
31 Dec 21 | 5,332 | -43,558 | 13,279 | 41,034 |
Quality Earnings: A298380 is currently unprofitable.
Growing Profit Margin: A298380 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A298380's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A298380's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A298380 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: A298380 has a negative Return on Equity (-75.26%), as it is currently unprofitable.